Abstract
Inflammatory bowel disease (IBD) is frequently associated with extraintestinal manifestations, notably hepatic injury. Milk fat globule membrane (MFGM), a bioactive component of milk, possesses significant anti-inflammatory potential. This study investigated the prophylactic effects of MFGM on dextran sulfate sodium (DSS)-induced acute colitis and secondary liver injury in mice. Prophylactic MFGM treatment significantly mitigated clinical symptoms, including body weight loss and disease activity index (DAI) scores, while preserving colonic length and histological integrity. Mechanistically, MFGM strengthened the intestinal mucus barrier by upregulating mucin and antimicrobial peptide genes, rebalanced the gut microbiota by enriching beneficial genera like Faecalibaculum, and reduced hepatic oxidative stress. These findings suggest MFGM as a promising dietary intervention for managing IBD and its systemic complications.
Introduction
Inflammatory Bowel Disease (IBD) is a chronic condition characterized by uncontrolled immune responses in the gastrointestinal tract. However, IBD is rarely limited to the gut; approximately 5% of patients develop secondary hepatobiliary disorders, such as fatty liver or cirrhosis, through the "gut-liver axis." When the intestinal barrier fails, toxins and bacteria translocate to the liver, causing secondary damage. While Milk Fat Globule Membrane (MFGM)—the bioactive trilayer surrounding fat droplets in milk—is known for its anti-inflammatory properties, its specific role in protecting the gut-liver axis remained poorly understood. This study sought to determine if MFGM could serve as a dietary intervention to prevent both primary intestinal inflammation and subsequent hepatic injury.
Methods
The researchers utilized a C57BL/6J mouse model of colitis. The experimental design involved a 21-day prophylactic phase where mice received MFGM via oral gavage, followed by a 7-day challenge with 4% Dextran Sulfate Sodium (DSS) in their drinking water to induce acute colitis. A multi-omics approach was employed to map protective mechanisms, including transcriptomics (RNA-seq) of colonic and hepatic tissues, 16S rRNA sequencing of fecal microbiota, and histological analysis using H&E and Alcian blue staining. Biochemical assays quantified cytokines (IL-1β, IL-6, IL-10) and oxidative stress markers (SOD, CAT, MDA).
Results
Clinical and Histological Improvements
Mice treated with MFGM showed significantly less body weight loss and lower Disease Activity Index (DAI) scores compared to the DSS-only group. Furthermore, MFGM treatment effectively prevented the colonic shortening typically observed in acute colitis.
Histological examination via H&E staining confirmed that MFGM-treated mice maintained superior tissue integrity, suffering significantly less crypt loss and structural damage than untreated colitis mice.
Molecular and Microbiome Modulation
MFGM treatment suppressed pro-inflammatory cytokines (IL-1β and IL-6) while boosting the anti-inflammatory cytokine IL-10 in both the colon and liver. Transcriptomic analysis revealed a striking upregulation of barrier-associated genes, including MUC2, MUC4, Reg3b, and Reg3g. These genes encode mucins and antimicrobial peptides that form a "chemical wall" against pathogens. Microbiome analysis showed that MFGM enriched beneficial genera such as Faecalibaculum and Roseburia, which are known butyrate producers that support colonocyte health.
Secondary Liver Protection
The protection extended to the liver, where MFGM treatment significantly lowered hepatic enzymes (AST and ALT) and reduced levels of Malondialdehyde (MDA), a marker of lipid peroxidation. This was linked to the upregulation of the glutathione transferase activity pathway, boosting the liver's internal antioxidant defenses.
Discussion and Conclusion
The study demonstrates that MFGM acts as a potent prophylactic agent against acute colitis and associated secondary liver injury. By fortifying the intestinal mucus barrier and promoting a healthy gut microbiome, MFGM mitigates systemic inflammation and reduces hepatic oxidative stress. A strong correlation was found between colonic barrier integrity (specifically Reg3 levels) and reduced hepatic injury markers, reinforcing the critical role of the gut-liver axis. While this study focused on prophylactic treatment, future research should explore MFGM's therapeutic potential in existing colitis and other liver conditions. These findings highlight MFGM as a valuable functional food supplement for maintaining gut and liver health.
Summary updated